Evolus

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evolus reports robust Q4 earnings, eyes international expansion and profitability

Evolus' Q4 2022 performance exceeded expectations, driven by strong revenue growth and customer acquisition.
The company's strategic focus on market share gains, international expansion, and profitability sets a positive trajectory.
Challenges from new competition and market dynamics require strategic responses to maintain leadership.
Opportunities in international expansion, corporate development, and market growth position Evolus for future success.

Evolus secures strategic partnership for growth in dermal filler market

Evolus' strong Q1 performance and strategic partnership with Symatese position the company for significant growth in the dermal filler market.
While facing challenges in safety comparisons and patient demographics, Evolus has opportunities to leverage its unique manufacturing process and upcoming data releases for market advantage.
Overall, Evolus is well-funded, poised for profitability, and focused on differentiating its product line for long-term success.

Evolus (EOLS) exceeds Q2 sales targets, eyes international expansion

Evolus (EOLS) delivered a strong performance in Q2, with accelerated sales growth, efficient cost management, and a focus on profitability, positioning the company for future success.
While facing challenges in market penetration and profitability, Evolus's strategic strengths in customer acquisition, innovation, and financial discipline provide a solid foundation for growth.
With opportunities for revenue expansion, international market growth, and disruptive product launches, Evolus is poised to capitalize on its strengths and address key challenges to drive long-term value for investors.

Evolus (EOLS) achieves record revenue and profitability, eyes global expansion

Evolus (EOLS) delivered a stellar performance in Q3 2023, with record revenue, strong financials, and promising R&D outcomes, positioning the company for continued growth and profitability.
The company's strategic strengths lie in market expansion, brand loyalty, and a clear long-term vision, supported by confidence in achieving ambitious revenue targets and product innovation.
While challenges in market competition and resource optimization persist, Evolus has opportunities in market segments, international expansion, and industry visibility to drive future growth.

Evolus surpasses revenue targets, eyes $700 million goal by 2028

Evolus delivered strong financial performance in Q4 2023, exceeding revenue expectations and achieving profitability. With a strategic focus on market expansion, product differentiation, and customer engagement, the company aims to reach a revenue target of $700 million by 2028.

Evolus reports robust Q1 growth, eyes $700M revenue target by 2028

Evolus demonstrated strong financial performance and market expansion in Q1 2024, with a focus on operational efficiency and customer engagement. The company's strategic goals include achieving profitability by year-end and targeting substantial revenue growth by 2028.
While facing challenges in market dynamics and profitability targets, Evolus remains optimistic about its competitive position and growth prospects. Opportunities lie in leveraging loyalty programs, expanding internationally, and launching new product lines to drive future success.

Evolus reports profitable Q2, eyes global expansion and new products

Evolus demonstrated strong performance in Q2 2024, achieving profitability and revenue growth.
The company's focus on innovation, international expansion, and financial management positions it for future success.
Challenges lie in maintaining growth momentum, executing expansion plans, and managing costs effectively.
Opportunities include capitalizing on market demand, global expansion, product innovation, and financial optimization.

Evolus reports strong Q3 growth, eyes $700M revenue target

Evolus showcased robust growth and strategic initiatives in Q3 2024, aiming for significant revenue targets by 2028. While facing revenue challenges and market competition, the company's strengths in product innovation and market expansion offer opportunities for sustained growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)---- $EOLS #EOLS--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Evolus, Inc.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Evolus, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019 and July 6, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Evolus investors under the federal securities laws. To join the Evolus class action, go to http://www.rosenlegal.com/cases-register-1954.html or call Phillip Kim, Esq. toll-free at 866-

ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Evolus, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm – EOLS

New York, New York--(Newsfile Corp. - October 14, 2020) -  Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Evolus, Inc. ("Evolus" or the "Company") (NASDAQ:EOLS).If you suffered losses exceeding $50,000 investing in Evolus stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/EOLS. There is no cost or obligation to you.

Evolus Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Evolus, Inc. To Contact The Firm

Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Evolus (EOLS) Stock?

New York, New York--(Newsfile Corp. - October 5, 2020) -  Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders Evolus, Inc. (NASDAQ: EOLS) resulting from allegations that Evolus may have issued materially misleading business information to the investing public.An International Trade Commission judge issued a preliminary ruling on trade secrets action involving Evolus on July 6, 2020. The non-binding decision sided with Allergan and its...

ROSEN, LEADING INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Evolus, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - EOLS

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Evolus, Inc. (NASDAQ: EOLS) resulting from allegations that Evolus may have issued materially misleading business information to the investing public. An International Trade Commission judge issued a preliminary ruling on trade secrets action involving Evolus on July 6, 2020. The non-binding decision sided with Allergan and its part

EOLS LOSS NOTICE: Rosen Law Firm Announces Investigation of Securities Claims Against Evolus, Inc. – EOLS

LOS ANGELES--(BUSINESS WIRE)---- $EOLS #EOLS--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Evolus, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Evolus, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - September 13, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Evolus, Inc.

Evolus Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Evolus, Inc. To Contact The Firm

NEW YORK--(BUSINESS WIRE)---- $EOLS #classaction--The law firm of Kirby McInerney LLP is investigating potential claims against Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS).

INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Evolus, Inc.

New York, New York--(Newsfile Corp. - September 11, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Evolus, Inc.

Evolus Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Evolus, Inc. To Contact The Firm

LOS ANGELES--(BUSINESS WIRE)---- $EOLS #EOLS--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Evolus, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Evolus, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

NEWPORT BEACH, Calif., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in three upcoming virtual investor conferences.

Evolus to Participate in Three Upcoming Investor Conferences

Aptinyx Inc

CymaBay Therapeutics

iBio

Sientra

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Red-Hot Biotech and Medtech Stocks Under $10 With Massive Upside Potential

Evolus Inc. (EOLS) CEO David Moatazedi on Q2 2020 Results - Earnings Call Transcript

Q2 2020 Net Revenue $7.8 Million, Up from $2.3 Million in Q2 2019

Evolus Reports Second Quarter 2020 Results and Provides Business Update

On Monday, August 10, Evolus (NASDAQ: EOLS) will release its latest earnings report.

Earnings Outlook For Evolus

Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Evolus (EOLS)

NEWPORT BEACH, Calif., July  27, 2020  (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its second quarter 2020 financial results and provide a business update on Monday, August 10, 2020 after the close of the U.S. financial markets.

Evolus to Report Second Quarter 2020 Financial Results and Provide a Business Update on Monday, August 10, 2020

Pro Forma Cash¹ Position of $125 Million at June 30, 2020 Pro Forma Cash¹ Position of $125 Million at June 30, 2020

Evolus Strengthens Balance Sheet; Secures $40 Million Investment

Commission to Review Case; Final Determination Targeted for November 2020

Evolus Provides Update on United States International Trade Commission (USITC) Case

Implied Volatility Surging for Evolus (EOLS) Stock Options

Evolus: Jeuveau Can Weather The Coronavirus Storm

Evolus' (EOLS) CEO David Moatazedi on Q1 2020 Results - Earnings Call Transcript

NEWPORT BEACH, Calif., April  16, 2020  (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced a pre-emptive plan to support the U.S. aesthetic neurotoxin market in light of the COVID-19 pandemic.

Evolus Provides Strategic Business Update

Company Remains Confident in its Intellectual Property and the Overall Merits of the Case Company Remains Confident in its Intellectual Property and the Overall Merits of the Case

News for Evolus Stock (EOLS)